JH

Jared Holz

Person

Heard in 1 episode across 1 show since Oct 2026

Jared Holz is a healthcare equity strategist and sector specialist at Mizuho. He is known for providing market analysis on healthcare and biotechnology companies.

Episodes

1
across 1 show

First heard

Oct 2026

Guest appearances

1

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Nov 20250
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20260
Sep 20260
Oct 20261

What Jared Holz has said on podcasts

3 statements

  1. on Eli Lilly and CompanyPositiveOct 14, 2026· Closing Bell

    Eli Lilly appears best positioned among major pharmaceutical companies over five years.

    “I think most around the street think that Eli Lilly is in the best shape over the next five years, just given what they've been able to accomplish and the pipeline.”

    Listen at 26:51

    Open the episode · AI Trade Faces a Reality Check 10/14/26
  2. on Johnson & Johnson pharmaceutical businessPositiveOct 14, 2026· Closing Bell

    Johnson & Johnson’s pharmaceutical business is among the best positioned.

    “J&J, even though the stock was down a lot yesterday because of issues they're having in medical devices, that pharma business within J&J looks to be one of the best.”

    Listen at 26:59

    Open the episode · AI Trade Faces a Reality Check 10/14/26
  3. on AbbVie and BiogenPositiveOct 14, 2026· Closing Bell

    AbbVie and possibly Biogen rank behind the strongest pharmaceutical opportunities.

    “And then I would probably say AbbVie and maybe Biogen after that.”

    Listen at 27:07

    Open the episode · AI Trade Faces a Reality Check 10/14/26

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

1 episode featuring Jared Holz, newest first